RecruitingPhase 2NCT07108777

L-Carnitine Protective Effect in Nephrotoxicity

Clinical Study to Evaluate the Possible Protective Effect of L-Carnitine Against Cisplatin-Induced Nephrotoxicity

Sponsor

Tanta University

Enrollment

46 participants

Start Date

Aug 10, 2025

Study Type

INTERVENTIONAL

Conditions

Nephrotoxicity

Summary

The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is: Does L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity?

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called L-Carnitine Tartrate and a drug called Placebo for people with nephrotoxicity. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGL-Carnitine Tartrate

L-carnitine 350 mg three times daily by oral.

DRUGPlacebo

placebo tablet three times daily by oral.

Locations(1)

Menoufia Clinical Oncology Department, Menoufia University.

Shibīn al Kawm, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07108777

Related Trials